Skip to main content
Premium Trial:

Request an Annual Quote

Sequencing MDx Firm Sequenta Raises $20M in Series C Round

NEW YORK (GenomeWeb News) – Sequenta has completed a Series C financing round, raising $20 million, it said on Tuesday.

Proceeds will go toward the commercial scale-up and clinical validation of its next-generation sequencing-based ClonoSight Test for minimal residual disease in leukemia and lymphoma.

Foresite Capital Management led the round, and all inside investors participated, Sequenta said, including MDV and Index Ventures. In addition, Jim Tananbaum, managing director of Foresite Capital, has joined Sequenta's board.

The South San Francisco, Calif.-based firm started offering ClonoSight in February through its CLIA-certified laboratory. The test uses the LymphoSight technology, an immune cell receptor-focused platform, which sequences unique DNA signatures present in immune cells, allowing the tracking of malignant sub-populations that are present even at one cell per million white blood cells, Sequenta said. Test results, which are generated in seven days, can be used to predict a patient's risk of post-treatment relapse and to guide treatment.

"We believe this financing will help to solidify our position as the market leader and allow us to broadly offer the first clinically actionable sequencing-based MRD test, "Tom Willis, CEO of Sequenta, said in a statement.

The company raised $13 million in its Series B financing round in 2010.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.